文献速递胸部肿瘤

细胞学细胞块适用于肺癌PD-L1免疫组化检测

Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究纳入1419例非小细胞肺癌连续病例,评估细胞学细胞块用于PD-L1免疫组化检测的可行性。结果显示92%细胞块肿瘤细胞数量充足,TPS≥50%在细胞块中占42%,高于小活检的36%(P=0.04)和手术标本的29%(P=0.001),固定方法不影响染色。结论认为以TPS≥50%为终点时细胞块检测表现良好,可作为晚期NSCLC PD-L1检测的有价值资源。

要点

  • 92%细胞学细胞块肿瘤细胞数量充足,与小活检无显著差异。
  • 细胞块TPS≥50%比例为42%,高于小活检36%和手术标本29%。
  • 固定方法不影响PD-L1免疫染色,高级别分期与更高TPS相关。

核心结论

  • 以TPS≥50%为终点时,细胞学细胞块PD-L1免疫组化检测表现良好。

研究设计与样本

  • 连续纳入1419例NSCLC,含371例细胞学细胞块、809例小活检和239例手术标本。
  • 细胞块采用福尔马林、甲醇/酒精或两者联合固定,以Dako PD-L1 IHC 22C3 pharmDx试剂盒染色。
  • TPS分类为<1%、1%-49%和≥50%,要求100个存活肿瘤细胞方为合格。

主要发现

  • 92%细胞学细胞块肿瘤细胞数量充足,与小活检无显著差异。
  • TPS≥50%在细胞块中占42%,小活检占36%(P=0.04),手术标本占29%(P=0.001)。
  • 福尔马林固定标本PD-L1高表达率为42%,甲醇/酒精联合福尔马林固定为40%(NS)。
  • PD-L1高表达率与EGFR、ALK或KRAS分子改变无关,IV期与更高PD-L1 TPS相关(P=0.001)。

关键数值与推荐

  • TPS≥50%定义为肿瘤细胞阳性比例≥50%,细胞块中该比例为42%。
  • PD-L1检测合格标准为至少有100个存活肿瘤细胞。

临床怎么用

  • 晚期NSCLC可考虑使用细胞学细胞块进行PD-L1免疫组化检测。
  • 细胞块固定方法不影响PD-L1染色结果,可灵活选择。

局限性

  • 细胞学标本中更高PD-L1免疫组化评分的临床意义需前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PD-L1 immunohistochemistry (IHC) testing is usually carried out on tissue blocks from core needle biopsy or surgical resections. In this study, we assessed the feasibility of using cytology cell blocks for PD-L1 IHC assay. METHODS: A total of 1419 consecutive cases of non-small-cell lung cancer (NSCLC), including 371 cytology cell blocks, 809 small biopsies, and 239 surgical specimens, were included in the study. The cytology cell blocks were prepared with formalin only, methanol/alcohol only or both. PD-L1 expression was examined by staining with Dako PD-L1 IHC 22C3 pharmDx kit. A Tumor Proportion Score (TPS) was categorized as <1%, 1%-49% and ≥50% tumor cells. A total of 100 viable tumor cells were required for adequacy. RESULTS: Of the cytology cell blocks, 92% of the specimens had an adequate number of tumor cells, not significantly different from small biopsies. The rate of TPS ≥50% differed between sample types and was observed in 42% of cytology cell blocks versus 36% of small biopsies (P = 0.04), and 29% of surgical resections (P = 0.001). The fixative methods did not affect the immunostaining, with overall PD-L1 high expression (TPS ≥50%) rates of 42% in formalin-fixed specimens versus 40% in specimens with combined fixation by methanol/alcohol and formalin (NS). The PD-L1 high expression rate was not associated with EGFR, ALK or KRAS molecular alterations. Higher stage (IV) was associated with higher PD-L1 TPS (P= 0.001). CONCLUSION: Our results show that when the TPS ≥50% is used as the end point, PD-L1 IHC performs well with cytology cell blocks. Cell blocks should be considered as a valuable resource for PD-L1 testing in advanced NSCLC. The clinical significance of higher PD-L1 IHC scores in cytology specimens needs to be evaluated prospectively.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wang H, Agulnik J, Kasymjanova G, et al. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Ann Oncol. 2018. PMID: 29659668. doi:10.1093/annonc/mdy126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。